重组人血小板生成素治疗特发性和血液肿瘤化疗后血小板减少症的Ⅲ期临床研究
急性白血病,,重组人血小板生成素;,急性白血病;,特发性血小板减少性紫癜;,非霍奇金淋巴瘤;,临床试验,Ⅲ期,0引言,1
·研究原著·Treatment of thrombocytopenia with recombinant human thrombopoietin in patients with idiopathic thrombocytopenic purpura and hematological malignancies following chemotherapy: Phase Ⅲ clinical cohort study
CHEN XieQun, BAI QingXian, WANG YiWei, ZHANG YongQing, ZHANG Tao, WANG WenQing, DONG BaoXia, QIAO QingDa, ZHANG WeiPing
Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an 710033, China
【Abstract】 AIM: To assess the clinical safety and efficiency of recombinant human thrombopoietin (rhTPO) for treatment of idiopathic and chemotherapyinduced thrombocytopenia. METHODS: Four patients with nonHodgkin’s lymphoma (NHL) entered randomized, crosscontrolled group, and 6 patients with acute leukemia for consolidation treatment entered nonrandomized, selfcontrolled group. Also, 9 patients with refractory idiopathic thrombocytopenic purpura (ITP) were enrolled in the trial. rhTPO was daily administered subcutaneously at a dose of 1 μg/kg for a duration of 14 days. All the trial data were analyzed with statistical software SPSS 10.0. RESULTS: After therapy with rhTPO in patients with hematological malignancies, both median platelet count and median peak platelet count were increased; there was significant difference in median differential platelet count between trial cycle and control cycle (P<0.05); the days with platelet count <50×109/L and days for platelet recovering ≥75×109/L or ≥100×109/L were shorter to a different degree. After treatment of refractory ITP with rhTPO, the median platelet count gradually rose to maximum of 101×109/L; the median differential platelet count between before and after administration was 85.67×109/L; the days for platelet count ≥30×109/L, ≥50×109/L and ≥100×109/L were 9.89, 13.56 and 19.78, respectively. CONCLUSION: rhTPO seems to be safe and may attenuate idiopathic or chemotherapyinduced thrombocytopenia without obviously adverse action. ......
您现在查看是摘要页,全文长 11663 字符。